TREM-like transcript 1 protein (TLT-1)

TREM-like transcript 1 protein (TLT-1) is a specialized member of the triggering receptor expressed on myeloid cells (TREM) family, uniquely sequestered within the alpha-granules of platelets and megakaryocytes. Upon platelet activation by stimuli such as thrombin or LPS, TLT-1 is rapidly translocated to the cell surface where it plays a critical role in hemostasis by facilitating platelet aggregation through its interaction with fibrinogen. Beyond its structural role in clot formation, TLT-1 is released as a soluble fragment (sTLT-1) that functions as a potent endogenous regulator of the innate immune response. This soluble form acts to dampen the pro-inflammatory amplification typically driven by TREM-1 on neutrophils and monocytes, making it a key protective factor against hyper-inflammation in conditions like sepsis. In clinical pathology, sTLT-1 is a valuable biomarker; its plasma levels correlate strongly with the severity of sepsis, disseminated intravascular coagulation (DIC), and the progression of coronary artery disease. Therapeutic development focuses on two main fronts: utilizing TLT-1-derived peptides (such as LR12) to treat acute inflammatory syndromes by inhibiting TREM-1 signaling, and developing antibodies to modulate platelet function in thrombotic or hemorrhagic disorders. Because of its dual role in coagulation and inflammation, TLT-1 represents a unique bridge between the hematologic and immune systems, offering a novel target for precision medicine in critical care and cardiovascular health.

Other names

TREML1Triggering receptor expressed on myeloid cells-like 1TLT1GLTL1825PRO3438dJ238O23.3

TLT-1 facilitates platelet aggregation by binding to fibrinogen and linking it to the platelet cytoskeleton via ezrin/radixin/moesin proteins. Soluble forms (sTLT-1) and derived peptides (like LR12) act as decoy receptors that competitively inhibit TREM-1 ligands, thereby dampening hyper-inflammatory signaling in myeloid cells.